CurrentUnitedHealthcarePolicy PAIN 025.5

Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Defines UnitedHealthcare Oxford coverage stance that percutaneous neuroablation is medically necessary for pancreatic cancer pain, severe cancer pain, and trigeminal neuralgia, and points to InterQual neuroablation criteria for medical necessity details; applies to members under UnitedHealthcare Oxford plans unless otherwise excluded.

Policy Summary

PayerUnitedHealthcare

PolicyPercutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia

Policy CodePolicy PAIN 025.5

Change TypeRevised (documentation protocol) — material

Effective DateOct 1, 2024

Next Review Date

Key ActionRefer prior authorization requests to InterQual Procedures, Neuroablation, Percutaneous and ensure required medical records per the Medical Records Documentation protocol are submitted.

SourceLink

POLICY UPDATE CHANGES

Related Policies: Added reference link to the Clinical Policy titled Sympathetic Blockade.

Replaced list of required clinical information with instruction to refer to the protocol titled Medical Records Documentation Used for Reviews.

Archived previous policy version PAIN 025.4.

3covered indications named

PAIN 025.5policy identifier

InterQual 2023externally referenced criteria version

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Medically Necessary Indications

Covered when the InterQual Percutaneous Neuroablation criteria are met for the specific indication

Covered Indications: Percutaneous neuroablation is considered proven and medically necessary for (1) pancreatic cancer pain, (2) severe cancer pain, and (3) trigeminal neuralgia.

Refer to InterQual Procedures, Neuroablation, Percutaneous for the detailed clinical entry criteria and required documentation.

Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service; benefit coverage for health services is determined by the member specific benefit plan document and applicable laws.

Inclusion of codes in the Applicable Codes section is provided for reference only and does not guarantee coverage; coverage decisions remain subject to the member-specific benefit plan and applicable laws.

Coding and References

Applicable procedure codes (examples provided)CPT

64600	Destruction by neurolytic agent; trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch.
64605	Destruction by neurolytic agent; trigeminal nerve; second and third division branches at foramen ovale.
64610	Destruction by neurolytic agent; trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring.
64620	Destruction by neurolytic agent; intercostal nerve.
64640	Destruction by neurolytic agent; other peripheral nerve or branch.

Medical necessity reference — InterQual

Reference standardInterQual Procedures, Neuroablation, Percutaneous (InterQual 2023)

Use for medical necessityRefer to InterQual criteria for detailed clinical entry requirements and prior authorization determination.

Applicable indicationsUsed to assess percutaneous neuroablation for pancreatic cancer pain, severe cancer pain, and trigeminal neuralgia.

Provider Actions and Requirements

Prior Authorization

Prior Authorization per InterQual Criteria

Prior authorization is required per InterQual neuroablation criteria. Coverage is subject to medical necessity; refer to InterQual Procedures, Neuroablation, Percutaneous (InterQual 2023).

Applicable when requesting percutaneous neuroablation procedures
Check member-specific benefits to confirm coverage

Step Therapy

Conservative Therapy Prior to Neuroablation for TN

A trial of conservative medical management is expected prior to neuroablation for trigeminal neuralgia (TN). First-line therapy typically includes analgesic and/or antiepileptic drugs; neuroablation is considered when TN is refractory to pharmacotherapy.

Document trials of appropriate medications and response prior to authorization
Include dates, medications, dosages, and clinical response in records

Definitions

Percutaneous Neuroablation — definition

Procedure descriptionPercutaneous Neuroablation: procedure to destroy neural tissue to relieve pain using chemical agents (phenol or alcohol) or thermal application (radiofrequency heat or cryoneurolysis).

Chemical neuroablationPercutaneous administration of phenol or alcohol around a nerve to denervate it.

Thermal neuroablationPercutaneous application of heat (radiofrequency) or cold (cryoneurolysis) to the nerve.

Trigeminal Neuralgia — definition

Syndrome definitionTrigeminal Neuralgia (TN) is a neuropathic syndrome affecting the trigeminal nerve characterized by severe electric shock-like painful episodes in one or more divisions of the nerve.

Typical presentation

Background

Percutaneous neuroablation relieves pain by destroying or denervating neural tissue using either chemical agents (for example, phenol or alcohol) that produce neurolytic injury, or thermal methods such as radiofrequency ablation or cryoneurolysis that apply heat or cold to disrupt nerve function.

Conservative Treatment Requirements

Trial of Pharmacotherapy Prior to Neuroablation for Trigeminal Neuralgia

Required conservative therapy before neuroablation for trigeminal neuralgia

Standard preprocedure care for Trigeminal Neuralgia: A trial of pharmacologic therapy (analgesic and/or antiepileptic drugs) is expected as standard care and neuroablation is indicated when trigeminal neuralgia is refractory to pharmacotherapy.

Document prior pharmacotherapy and inadequate response in the medical record per the Medical Records Documentation protocol.

Frequency Limits

Frequency limits

Frequency limits statementNo explicit frequency limits stated in policy.

ImplicationCoverage frequency determinations should follow InterQual criteria and member-specific benefit terms when not specified here.

Documentation noteAbsence of stated limits does not guarantee coverage; applicable laws and benefit plan terms apply.

Imaging Requirements

Billing Rule

Use radiologic monitoring for specified trigeminal neurolytic approaches (e.g., CPT 64610)

Trigeminal nerve neurolytic procedures performed at the foramen ovale (CPT 64610) are specified as being performed 'under radiologic monitoring' where applicable; radiologic monitoring/fluoroscopy is required for certain CPT-coded approaches.

CPT 64610: Destruction by neurolytic agent; trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring.
Policy notes that fluoroscopy/imaging is required for percutaneous neuroablation procedures where indicated.

Not Covered / Exclusions

This policy does not list specific procedures or indications as definitively not covered. Coverage determinations remain subject to the member's benefit plan terms and applicable laws; absence of an explicit exclusion in this document does not guarantee coverage.